OBJECTIVE: To compare the image quality of contrast-enhanced magnetic resonance angiography (CE-MRA) of the supra-aortic vessels at 0.05 mmol/kg bw and 0.1 mmol/kg bw, between gadobutrol, Gd-DTPA and Gd-BOPTA quantitatively and qualitatively a total of eight pigs were evaluated (…)
[Read article]
[Source: NCBI PubMed]
RATIONALE AND OBJECTIVES: The donor atoms that bind to gadolinium in contrast agents influence inner-sphere water exchange and electronic relaxation, both of which determine observed relaxivity. The effect of these molecular parameters on relaxivity is greatest when the (…)
[Read article]
[Source: NCBI PubMed]
September 7, 2010 - Bayer Schering Pharma has launched SciLin, its recombinant insulin product, in China. In June 2009, the company paid $43.5 million to Polish biotech Bioton for China rights to the drug over the next 15 years. At the time of the agreement, Bayer forecast (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/61183d/womens_health_the) has announced the addition of the "Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in (…)
[Read article]
[Source: Business Wire]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Company management will present at multiple investor conferences this month. The live webcast of each (…)
[Read article]
[Source: Business Wire]
31.08.2010 - IBA (Ion Beam Applications S.A.) announced that they have entered into an agreement with Bayer Schering Pharma AG, Germany (Bayer) for chemical process development and clinical trial doses supply of FLORBETABEN, a molecular imaging compound in development for the (…)
[Read article]
[Source: Bionity.com]
LOS ANGELES-(BUSINESS WIRE)-KYTHERA Biopharmaceuticals, Inc. ( KYTHERA ) and Intendis, Bayer HealthCare s dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA s lead product candidate, ATX-101, outside (…)
[Read article]
[Source: Business Wire]
Louvain-la-Neuve, Belgium, August 27th, 2010 IBA (Ion Beam Applications S.A.) announced today that they have entered into an agreement with Bayer Schering Pharma AG, Germany (Bayer) for chemical process development and clinical trial doses supply of FLORBETABEN, a molecular (…)
[Read article]
[Source: BioSpace]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN - News), a biotechnology company that develops antibody-based targeted anticancer products, today announced that Genentech, a member of the Roche Group, today announced its receipt of a Refuse to File (RTF) letter (…)
[Read article]
[Source: BioSpace]
Cancer Research Technology has signed an agreement with Bayer Schering Pharma AG, Germany to evaluate new leptin antagonist peptides as potential experimental treatments initially in the area of gynaecological diseases, including cancer. Under the terms of the agreement, Bayer (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bf790f/competitor_analysi) has announced the addition of the "Competitor Analysis: Tau and Amyloid Beta Targeted Therapy of Alzheimers Disease" report to their offering. Competitor (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Biomarker research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - (…)
[Read article]
[Source: Business Wire]
OBJECTIVE: To compare the efficacy and safety of the levonorgestrel-releasing intrauterine system and oral medroxyprogesterone acetate in the treatment of idiopathic heavy menstrual bleeding. METHODS: In this multicenter, randomized, controlled study, women aged 18 years or (…)
[Read article]
[Source: NCBI PubMed]
RATIONALE AND OBJECTIVES: Quantification of targeted ultrasound contrast agents allows for the monitoring of endothelial marker expressions on a molecular level. In this study, a statistical correction is provided, which allows for improved precision in estimating the (…)
[Read article]
[Source: NCBI PubMed]
The dissociated glucocorticoid receptor (GR) agonist ZK 216348 is rendered GR-selective over other nuclear hormone receptors through replacing the methylbenzoxazine with a quinoline moiety. Compounds were shown to be efficacious in cell assays with respect to inflammation (…)
[Read article]
[Source: NCBI PubMed]
Potent and selective adenosine A(1) receptor antagonists were disclosed. SAR and pharmacological profile of selected compounds were discussed. |-| Bioorg Med Chem Lett. |-| Griebenow N, Bärfacker L, Meier H, Schneider D, Teusch N, Lustig K, Kast R, Kolkhof P. |-| Bayer (…)
[Read article]
[Source: NCBI PubMed]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Osteoporosis research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible (…)
[Read article]
[Source: Business Wire]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/7f25f4/the_cardiovascular) has announced the addition of the "The Cardiovascular Market Outlook to 2015: Competitive Landscape, Global Market Analysis, Key Trends and Pipeline analysis" (…)
[Read article]
[Source: Business Wire]
Cambridge, UK, and Norwalk, Connecticut, USA, 12 August 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Psoriasis research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Psoriasis research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the (…)
[Read article]
[Source: Business Wire]
SEATTLE, WA-(Marketwire - August 10, 2010) - Mindbloom, Inc. today announced a partnership with Bayer HealthCare LLC. As part of the partnership, brokered by New York-based digital management consultancy FOCi Group, Bayer's One A Day brand will leverage Mindbloom's technology (…)
[Read article]
[Source: Marketwire]
BETHESDA, Md.-(BUSINESS WIRE)-Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that the Company will participate in the Canaccord Genuity 30th (…)
[Read article]
[Source: Business Wire]
Medical News Today - Bayer Schering Pharma AG, Berlin, Germany, announced today that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application to the U.S. for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance imaging (…)
[Read article]
[Source: BioSpace]
Bayer announced that a novel, convenient single-drug treatment approach with oral rivaroxaban met the primary efficacy endpoint of non-inferiority in the EINSTEIN-DVT Phase III clinical trial and showed an overall relative risk reduction compared to the current standard therapy (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/045efe/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Brazil" report to their offering. These highly regarded world pharmaceutical market reports have (…)
[Read article]
[Source: Business Wire]
Bayer today announced that a novel, convenient single-drug treatment approach with oral rivaroxaban met the primary efficacy endpoint of non-inferiority in the EINSTEIN-DVT Phase III clinical trial and showed an overall relative risk reduction compared to the current standard (…)
[Read article]
[Source: Medical News Today]
Bayer Schering Pharma AG, Berlin, Germany, announced today that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application to the U.S. for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance imaging (MRI). Gadovist 1.0 (…)
[Read article]
[Source: Medical News Today]
BETHESDA, Md.-(BUSINESS WIRE)-Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months (…)
[Read article]
[Source: Business Wire]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period and (…)
[Read article]
[Source: Business Wire]
BETHESDA, Md.-(BUSINESS WIRE)-Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review (…)
[Read article]
[Source: Business Wire]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN) announced today that the company will present at two investor conferences in the next two weeks. These presentations will be webcast live and can be accessed through the Investor Information section of the (…)
[Read article]
[Source: Business Wire]
While the Food and Drug Administration (FDA) requires a warning of an increased risk of suicide for all epilepsy drugs, a new study shows that only certain drugs may increase the risk. The study is published in the July 27, 2010, issue of Neurology, the medical journal of the (…)
[Read article]
[Source: Medical News Today]
WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops targeted anticancer products, today announced that the Company will host a conference call at 4:30 p.m. ET on Wednesday, August 4, 2010, to discuss ImmunoGen s financial (…)
[Read article]
[Source: Business Wire]
28.07.2010 - Bayer Schering Pharma AG, Germany, and Bayer Yakuhin, Ltd., Japan, announced that the Japanese regulatory authorities have granted approval for YAZ (3 mg drospirenone/20 mcg ethinyl estradiol) for the treatment of dysmenorrhea. YAZ is available in the US, Europe, (…)
[Read article]
[Source: Bionity.com]
DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Dermatology research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by (…)
[Read article]
[Source: Business Wire]
OBJECTIVE: To determine whether blood pool contrast agent-enhanced magnetic resonance imaging (MRI) can visualize endoleaks that are occult on computed tomography (CT) in patients with nonshrinking aneurysms after endovascular aneurysm repair. MATERIALS AND METHODS: Written (…)
[Read article]
[Source: NCBI PubMed]
The formation of lipid digestion products is a relevant parameter for effective in vivo performance of self-emulsifying drug delivery systems (SEDDS). These lipid-based formulations contain non-ionic surfactants, therefore the effects of polysorbate 80 (PS 80), (…)
[Read article]
[Source: NCBI PubMed]
OBJECTIVE: To determine whether blood pool contrast agent-enhanced magnetic resonance imaging (MRI) can visualize endoleaks that are occult on computed tomography (CT) in patients with nonshrinking aneurysms after endovascular aneurysm repair. MATERIALS AND METHODS: Written (…)
[Read article]
[Source: NCBI PubMed]
A collaborative trial was conducted to evaluate the possibility of integrating the rat-liver Comet assay into repeat-dose toxicity studies. Fourteen laboratories from Europe, Japan and the USA tested fifteen chemicals. Two chemicals had been previously shown to induce (…)
[Read article]
[Source: NCBI PubMed]
OBJECTIVE: To determine whether blood pool contrast agent-enhanced magnetic resonance imaging (MRI) can visualize endoleaks that are occult on computed tomography (CT) in patients with nonshrinking aneurysms after endovascular aneurysm repair. MATERIALS AND METHODS: Written (…)
[Read article]
[Source: NCBI PubMed]